Active substance
Docosanol
- US FDA 9
- UK MHRA 2
- US price lines 3
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| ABREVA | 10% | cream · topical | HALEON US HOLDINGS | Over-the-counter | 25 Jul 2000 |
| DOCOSANOL | 10% | cream · topical | P AND L | Over-the-counter | 19 Nov 2018 |
| DOCOSANOL | 10% | cream · topical | ALEMBIC | Over-the-counter | 3 May 2022 |
| DOCOSANOL | 10% | cream · topical | P AND L DEVELOPMENT | Over-the-counter | 7 Oct 2022 |
| DOCOSANOL | 10% | cream · topical | SUN PHARMA CANADA | Over-the-counter | 26 Oct 2023 |
| DOCOSANOL | 10% | cream · topical | AUROBINDO PHARMA LTD | Over-the-counter | 1 Mar 2024 |
| DOCOSANOL | 10% | cream · topical | DR REDDYS | Over-the-counter | 3 Oct 2025 |
| DOCOSANOL | 10% | cream · topical | DR REDDYS | Over-the-counter | 23 Oct 2025 |
| DOCOSANOL | 10% | cream · topical | KLM LABS PVT | Over-the-counter | 31 Jul 2026 |
UK MHRA United Kingdom — marketing authorisations
| Product | Authorisation | Holder | Legal status |
|---|---|---|---|
| BLISTEX COLD SORE CREAM | PL 53512/0002 | BLISTEX LIMITED | GSL |
| DOCOSANOL 10% CREAM | PL 52731/0003 | DENDRON BRANDS LIMITED | P |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | DOCOSANOL 10% CREAM | $5.79261 | per GM | 23 Sep 2026 |
| US NADAC | FT DOCOSANOL 10% CREAM | $5.79261 | per GM | 23 Sep 2026 |
| US NADAC | GNP DOCOSANOL 10% CREAM | $5.79261 | per GM | 23 Sep 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), MHRA category lists of UK marketing authorisations (Open Government Licence v3.0), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.